The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL
about
c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's diseaseResistant mutations in CML and Ph(+)ALL - role of ponatinib.Role of ABL family kinases in cancer: from leukaemia to solid tumoursMolecular Determinants Underlying Binding Specificities of the ABL Kinase Inhibitors: Combining Alanine Scanning of Binding Hot Spots with Network Analysis of Residue Interactions and CoevolutionIntramolecular dynamics within the N-Cap-SH3-SH2 regulatory unit of the c-Abl tyrosine kinase reveal targeting to the cellular membraneSRChing for the substrates of Src.Discovering and understanding oncogenic gene fusions through data intensive computational approachesThe BCR-ABL inhibitor ponatinib inhibits platelet immunoreceptor tyrosine-based activation motif (ITAM) signaling, platelet activation and aggregate formation under shear.The Role of New Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaAllosteric Inhibition of Bcr-Abl Kinase by High Affinity Monobody Inhibitors Directed to the Src Homology 2 (SH2)-Kinase InterfaceMyeloid Cell Origins, Differentiation, and Clinical Implications.Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.The war on cancer: are we winning?Detecting and targetting oncogenic fusion proteins in the genomic era.Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors.Opening the door to the development of novel Abl kinase inhibitors.Sphingosine-1-phosphate mediates a reciprocal signaling pathway between stellate cells and cancer cells that promotes pancreatic cancer growth.Target-based molecular modeling strategies for schistosomiasis drug discovery.NUP214-ABL1-mediated cell proliferation in T-cell acute lymphoblastic leukemia is dependent on the LCK kinase and various interacting proteins.Treatment-free remission in patients with chronic myeloid leukemia.Cell biology: a key driver of therapeutic innovation.Allosteric Communication Networks in Proteins Revealed through Pocket Crosstalk AnalysisParallelized Ligand Screening Using Dissolution Dynamic Nuclear Polarization.'One Health' for the people of Hong Kong and the world.Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase.Computational analyses of interactions between ALK-5 and bioactive ligands: insights for the design of potential anticancer agents.In silico studies on the interaction between bioactive ligands and ALK5, a biological target related to the cancer treatment.The SH2 domain of Abl kinases regulates kinase autophosphorylation by controlling activation loop accessibility.Allosteric targeting of receptor tyrosine kinases.Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey.
P2860
Q24318974-E7BE6650-2736-4FFE-BF6A-F7CC64F2D9B7Q27853085-394EA47C-C43E-4B57-A0CE-362CF2D9320EQ28396643-CD10F3B8-91C9-4E33-9636-761E8F2BD0D4Q28548366-2A5B3863-2FC7-4F08-9894-4DA9412E32E3Q30009592-C08D399C-4EB7-43CE-BA6B-2B9DDD28CB1CQ30457060-FBAC87EC-E0C3-4273-849D-ED263703D8FBQ31083417-074D668F-6C7A-43EC-B6D6-CCE5E3D0AE78Q34748167-CE52F3FE-F894-407D-ADF6-24BCA0603CF9Q36547224-3ACECD60-B772-483A-8120-95F2860DAC20Q36884733-A882A853-E041-4560-A756-6206635841A8Q37429070-B620C113-82FE-4226-8930-0A07E2DCB573Q37702115-9BA04032-0A1E-48CA-9508-6447EDCD3BF2Q38097382-FDF2BABB-1A7D-49A4-ABE2-B368464D3E8EQ38336067-EFB455C7-5E93-4004-9C95-EC43726B49E7Q38761171-6559D3FF-3D6B-4847-9C38-9C5F08CC3DBCQ38806783-3657412A-B2E2-4548-A821-BEFB96368327Q38967180-8BCA233A-241A-4519-B304-248E2E991A6EQ39003333-4E038555-B40F-4B68-9545-6487D1629670Q39122858-99D62D41-7E32-4614-BF3A-660493FC96EFQ39423384-BA0998DC-E3AB-4064-BF64-BF28868E14CEQ41265920-E0A00F4C-52EF-4A11-8F91-CEB5DD8261D5Q41815533-0F1DDF52-5977-479D-BFC3-2A41DF368297Q43275135-7630B86F-C5CF-4B17-8C59-0F3EE8E80E8FQ45358243-32D9A994-E730-44EB-86F1-CFCCD225B0A2Q47093610-86EF8608-31AB-48AA-BC88-3784974028B8Q47307704-1865268C-8CDE-4911-9AA7-6F296AEEE255Q50917379-AA0AC18A-6034-4BEE-825F-6521FC0A68E7Q52655033-86C87E8C-FBD3-4954-A5C4-6B29DEC3789EQ54310876-957261C8-1563-4D74-8E94-F6A4AECF24DCQ55345383-3E97A498-9E82-4D70-A3C1-1E561CC1D320
P2860
The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL
@ast
The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL
@en
The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL
@nl
type
label
The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL
@ast
The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL
@en
The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL
@nl
prefLabel
The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL
@ast
The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL
@en
The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL
@nl
P2860
P50
P3181
P1433
P1476
The growing arsenal of ATP-competitive and allosteric inhibitors of BCR-ABL
@en
P2860
P304
P3181
P356
10.1158/0008-5472.CAN-12-1276
P407
P577
2012-10-01T00:00:00Z